EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial

Chuck Chang iD, Yiming Zhang, Yun Chai Kuo iD, Min Du iD, Kyle Roh, Roland Gahler, Afoke Ibi, Julia Solnier iD

Pharmaceutics · 04.07.2025 · 17 (7) · 880

DOI: 10.3390/pharmaceutics17070880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.07.2025. Verfasst von Chuck Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: ISURA, Burnaby, BC V3N4S9, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISURA, Factors Group of Nutritional Companies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Silymarin, a flavonoid complex, and the main bioactive component of milk thistle (Silybum marianum), is known for its hepatoprotective properties but suffers from poor bioavailability due to its low solubility and extensive first-pass metabolism.

Method

This study aimed to evaluate the pharmacokinetics and tolerability of a novel micellar milk thistle formulation designed to enhance silymarin absorption, compared to an unformulated/standard milk thistle product, in a small-scale human bioavailability trial. In a randomized, double-blinded, crossover study, 16 healthy participants received a single dose of either the micellar formulation (LipoMicel Milk Thistle; LMM) or the standard formulation (STD) at a total daily dose of 130 mg silymarin. Blood concentrations were measured over 24 h, and key pharmacokinetic parameters—maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), and area under the curve (AUC)—were calculated. Tolerability and safety were assessed through adverse event monitoring during the study period.

Results

Results demonstrated a significant increase in bioavailability with the micellar formulation, with 18.9-fold higher Cmax (95% CI: 1.9–30.7 ng/mL vs. 74.4–288.3 ng/mL; p = 0.007) and 11.4-fold higher AUC0–24 (95% CI: 7.40–113.5 ng·h/mL vs. 178–612.5 ng·h/mL; p = 0.015). Tmax was 0.5 (95% CI: 0.5–4.0) hours for the micellar formulation versus 2.5 (95% CI: 0.5–8.0) hours for the standard product (p = 0.015) indicating faster absorption of LMM. The standard formulation exhibited a significantly longer mean residence time compared to the LMM formulation (95% CI: 4.4–7.5 h vs. 2.8–4.2 h; p = 0.015).

Conclusions

No adverse events or significant safety concerns were observed in either group. Compared to the standard, the micellar formulation showed superior pharmacokinetic outcomes, suggesting it may enhance silymarin’s clinical efficacy in liver health.

Schlagwörter

Stichwörter der Autor:innen

LipoMicelbioavailabilityhepatoprotectivehuman studyliver healthmicellesmilk thistlepharmacokineticssilymarin

Autor:innen und Institutionen

  • ISURA, Burnaby, BC V3N4S9, Canada.
  • Factors Group R & D, Burnaby, BC V3N4S9, Canada.

ORCID-Profile: Chuck Chang, Yun Chai Kuo, Min Du, Julia Solnier

Förderung

  • ISURA
  • Factors Group of Nutritional Companies

Zitieren

APA

Chang, C., Zhang, Y., Kuo, Y. C., Du, M., Roh, K., Gahler, R., Ibi, A., & Solnier, J. (2025). Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial. Pharmaceutics, 17(7), 880. https://doi.org/10.3390/pharmaceutics17070880

Vancouver

Chang C, Zhang Y, Kuo YC, Du M, Roh K, Gahler R, et al. Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial. Pharmaceutics. 2025;17(7):880. doi:10.3390/pharmaceutics17070880

BibTeX
@article{Chang2025,
  author = {Chang, Chuck and Zhang, Yiming and Kuo, Yun Chai and Du, Min and Roh, Kyle and Gahler, Roland and Ibi, Afoke and Solnier, Julia},
  title = {Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {880},
  doi = {10.3390/pharmaceutics17070880}
}
Kostenlos starten →